952394-82-0

Basic information

• Product Name: ethyl 4-(bromomethyl)-2-(4-fluorophenyl)thiazole-5-carboxylate
• Synonyms: ethyl 4-(bromomethyl)-2-(4-fluorophenyl)thiazole-5-carboxylate
• CAS NO: 952394-82-0
• Molecular Weight: 344.204
• Mol File: 952394-82-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 4-(bromomethyl)-2-(4-fluorophenyl)thiazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(bromomethyl)-2-(4-fluorophenyl)thiazole-5-carboxylate(952394-82-0)
• EPA Substance Registry System: ethyl 4-(bromomethyl)-2-(4-fluorophenyl)thiazole-5-carboxylate(952394-82-0)

Safety Data

• Hazardous Substances Data: 952394-82-0(Hazardous Substances Data)

Upstream product

• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 
• 22179-72-2 4-fluorothiobenzamide 
• 22900-83-0 ethyl 2-bromo-4-methyl-1,3-thiazole-5-carboxylate 
• 7210-76-6 ethyl-2-amino-4-methylthiazole-5-carboxylate 
• 317319-17-8 4-methyl-2-(4-fluorophenyl)thiazole-5-carboxylic acid ethyl ester 

Downstream Products

• 952394-83-1 4-{[(2,4-dimethoxy-benzyl)-ethoxycarbonylmethyl-amino]-methyl}-2-(4-fluoro-phenyl)-thiazole-5-carboxylic acid ethyl ester 

Relevant articles and documents

Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhi

SHP2 is a non-receptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell death pathway (PD-1/PD-L1) and cell growth and differentiation pathway (MAPK). Moreover, mutations in SHP2 have been implicated in Leopard syndrome (LS),

Design and synthesis of novel triazole derivatives containing γ-lactam as potential antifungal agents

A series of novel triazole derivatives containing γ-lactam were designed and synthesized, and their structures were confirmed by 1H NMR, 13C NMR and HRMS. The in vitro antifungal activities of the target compounds were evaluated. The results showed that all of the compounds exhibited stronger activity against the six clinically important fungi tested than fluconazole. 3D and 3E showed comparative activity against the fungi tested except for Candida glabrata and Aspergillus fumigatus as voriconazole. In addition, the docking model for 2A and CYP51 was investigated.